On 31 December 2025, Mabwell announced that it has received marketing approval from the Indonesian Food and Drug Authority for its Adalimumab Injection 9MW0113, biosimilar to AbbVie’s Humira®.
Mabwell jointly developed the biosimilar with Shanghai Junshi Biosciences and it was approved in China in March 2022, where it is marketed as Junmaikang®. Mabwell reports that it has signed formal cooperation agreements for 9MW0113 in more than ten countries and has submitted registration applications in multiple countries, including Jordan and Peru.
Mabwell’s biosimilar portfolio also includes Mailishu® and Maiweijian™, referencing Amgen’s Prolia® and Xgeva® (denosumab), which were approved in China in March 2023 and April 2024, respectively, and first launched outside of China in December 2025. According to Mabwell, it has submitted marketing authorisation applications for its denosumab biosimilars in several other key markets, including Jordan, Egypt, and Brazil.